What is the recommended cotrimoxazole (trimethoprim‑sulfamethoxazole) prophylaxis and treatment protocol for HIV‑infected patients, including dosing and duration based on CD4 count?

Cotrimoxazole Protocol in HIV

HIV-infected adults and adolescents should receive cotrimoxazole prophylaxis (one double-strength tablet daily) when CD4 count falls below 200 cells/µL or if they have oropharyngeal candidiasis, and this prophylaxis should be continued even after immune reconstitution on ART in settings with high infectious disease burden, particularly where malaria is endemic 1.

Indications for Starting Prophylaxis

Primary prophylaxis must be initiated when:

• CD4 count <200 cells/µL (strongest indication) 1
• History of oropharyngeal candidiasis (regardless of CD4 count) 1
• CD4 percentage <14% (consider prophylaxis) 1
• History of AIDS-defining illness (consider prophylaxis) 1
• CD4 count 200-250 cells/µL when monitoring is unreliable (consider prophylaxis) 1

Dosing Regimens

Standard Prophylaxis Dosing

Preferred regimen: One double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) daily 1

Alternative effective regimens:

• One single-strength tablet daily (better tolerated, equally effective) 1
• One double-strength tablet three times weekly 1

Treatment Dosing for Active PCP

For documented Pneumocystis pneumonia: 75-100 mg/kg sulfamethoxazole and 15-20 mg/kg trimethoprim per 24 hours, divided every 6 hours for 14-21 days 2

Critical Benefits Beyond PCP Prevention

The double-strength daily regimen provides crucial cross-protection against:

• Toxoplasmosis 1
• Common respiratory bacterial infections 1
• Malaria (46-97% reduction in malaria incidence in endemic areas) 3, 4
• Diarrheal illnesses (35-39% reduction) 5, 4

This multi-pathogen protection is particularly important as cotrimoxazole prophylaxis reduces overall mortality by 44-60% in HIV-infected patients 6, 4.

When to Discontinue Prophylaxis

The decision to stop cotrimoxazole is geography-dependent and should prioritize infectious disease burden over CD4 count alone.

In Non-Malaria Endemic Areas

Discontinuation can be considered when:

• CD4 count sustained >200 cells/µL for ≥3 months on ART 1
• Patient on stable antiretroviral therapy 1

In Malaria-Endemic or High Infectious Disease Burden Settings

Continue cotrimoxazole indefinitely regardless of CD4 recovery 3, 6. The evidence is compelling: stopping cotrimoxazole in Kenya resulted in a 33-fold increase in malaria cases despite CD4 counts >350 cells/µL 3. Similarly, continuation after immune reconstitution in Africa reduced hospitalizations by 58%, pneumonia by 27%, malaria by 97%, and diarrhea by 39% 5.

Managing Adverse Reactions

Common pitfall: Prematurely discontinuing cotrimoxazole due to rash or fever.

Correct approach:

• Continue therapy if reaction is not life-threatening 1
• After resolution, reinstitute with gradual dose escalation (desensitization) 1
• Up to 70% of patients can successfully tolerate reintroduction 1
• Consider reduced dose or frequency during reintroduction 1

Alternative agents if desensitization fails:

• Dapsone 100 mg daily 1
• Dapsone 50 mg daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly (provides toxoplasmosis coverage) 1
• Atovaquone 1500 mg daily (expensive but effective) 1
• Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer 1

Renal Dose Adjustment

When creatinine clearance is impaired 2:

• CrCl >30 mL/min: Standard dosing
• CrCl 15-30 mL/min: Half the usual dose
• CrCl <15 mL/min: Not recommended

Special Populations

Pregnant women: Should receive cotrimoxazole prophylaxis using the same CD4 thresholds 1. In Africa, cotrimoxazole is superior to intermittent preventive treatment for malaria, showing non-inferior outcomes for infant mortality, low birthweight, and placental malaria 6.

Children ≥2 months: 750 mg/m²/day sulfamethoxazole with 150 mg/m²/day trimethoprim, divided twice daily, three consecutive days per week (maximum 1600 mg sulfamethoxazole/320 mg trimethoprim daily) 2

Key Clinical Pearls

• Neutropenia is more common with cotrimoxazole continuation (hazard ratio 0.70) but is generally manageable and outweighed by infection prevention benefits 5
• Bacterial resistance to cotrimoxazole does not negate clinical benefit—even with 76% resistance rates in diarrheal pathogens, prophylaxis still reduced diarrhea by 35% and mortality by 46% 4
• The CD4-preserving effect: Cotrimoxazole slows CD4 decline (77 vs 203 cells/µL annual decline) and reduces viral load increase (0.08 vs 0.90 log₁₀ copies/mL annually) 4
• Geographic context is paramount: In malaria-endemic regions, the protective benefit against malaria alone justifies indefinite continuation regardless of immune recovery 3, 6